Skip to content
Study details
Enrolling now

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136)

Eli Lilly and Company
NCT IDNCT07215559ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

200

Study length

about 1.6 years

Ages

18–75

Locations

22 sites in AZ, GA, NJ +5

What this study is about

Researchers are testing macupatide and eloralintide, alone or in combination, to see if they help people with obesity or overweight who also have type 2 diabetes lose weight. The trial will last about 48 weeks.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Eloralintide
  • 2.Take Eloralintide Placebo
  • 3.Take Macupatide
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Percent Change from Baseline in Body Weight

Secondary: Change from Baseline in Body Mass Index (BMI), Change from Baseline in Fasting Glucose, Change from Baseline in Hemoglobin A1c (HbA1c)

Body systems

Endocrinology